Attovia Therapeutics, Inc.
NASDAQ:ATTOBiotechnology
-$0.18 today
- Market cap
- $709.92M
- Beta
- 0.00
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
Volume 0.34M
Average 0.45M
ATTO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Attovia Therapeutics, Inc.NASDAQ: ATTO
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin of $3.06M in Q2 FY2026
Q2 FY2026 selling, general & admin was $3.06M.
Context
- Selling, general & admin amounted to 1003.9% of revenue in FY2025.
Sources:Income StatementText generated from reported figures; not investment advice.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 13.55M USD
- Year-over-year change
- +83.7%
- 1-year CAGR
- +83.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.55M | +83.7% |
| FY2024 | 2024-12-31 | 7.38M | — |
Selling, General & Admin vs competitors
How ATTO compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +83.7% is the highest of 10, against a peer median of +17.2%.
- Selling, general & admin amounts to 1003.9% of revenue for ATTO, versus a peer median of 248.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $77.08M USD | +17.2% | +94.2% | 1041.9% |
| LTM Mar 2026 | $62.81M USD | +42.2% | +11.5% | 27.0% | |
| LTM Mar 2026 | $46.46M USD | +34.5% | +22.2% | — | |
ZURAZura Bio Limited | LTM Mar 2026 | $35.14M USD | +1.0% | +112.2% | — |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $29.26M USD | +41.9% | +59.4% | — |
EVMNEvommune, Inc. | LTM Mar 2026 | $22.64M USD | — | — | 226.4% |
| LTM Mar 2026 | $22.58M USD | +5.5% | -4.4% | 269.8% | |
| FY2025 | $20.34M USD | +5.8% | -0.8% | 31781.3% | |
| LTM Mar 2026 | $17.08M USD | -4.8% | +20.7% | 31.8% | |
| FY2025 | $13.55M USD | +83.7% | — | 1003.9% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | €9.82M EUR | +63.8% | — | — |
| Peer median (excluding ATTO) | — | +17.2% | +21.4% | 248.1% | |
Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 0 | 1.35M |
| Cost of Revenue | 313K | 804K |
| Gross Profit | (313K) | 546K |
| Gross Margin | — | 40.4% |
| Research & Development | 33.86M | 54.15M |
| Selling, General & Admin | 7.38M | 13.55M |
| Operating Expenses | 41.24M | 67.71M |
| Depreciation & Amortization | 313K | 804K |
| EBITDA | (41.24M) | (66.36M) |
| EBITDA Margin | — | -4915.2% |
| Operating Income | (41.55M) | (67.16M) |
| Operating Margin | — | -4974.7% |
| Interest Income | 3.44M | 6.63M |
| Interest Expense | 0 | 0 |
| Other Income / Expenses | 1.75M | 6.53M |
| Income Before Tax | (39.8M) | (60.63M) |
| Pre-Tax Margin | — | -4490.9% |
| Income Tax Expense | 0 | 0 |
| Net Income | (39.8M) | (60.63M) |
| Net Margin | — | -4490.9% |
| EPS (Basic) | (1.05) | (1.42) |
| EPS (Diluted) | (1.05) | (1.42) |
| Weighted Avg Shares | 43.03M | 43.03M |
| Weighted Avg Shares (Diluted) | 43.03M | 43.03M |
Attovia Therapeutics, Inc.
NASDAQ:ATTO
Intrinsic Alpha fair value
Locked
Current Price
$15.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.